1
|
Deepthi A, Leena SS, Krishnan D. Update on thiopyran-fused heterocycle synthesis (2013-2024). Org Biomol Chem 2024; 22:5676-5717. [PMID: 38912843 DOI: 10.1039/d4ob00497c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/25/2024]
Abstract
Thiopyrans and their fused derivatives have significant synthetic relevance owing to their biological importance and occurrence in natural products. The current article provides an overview of synthetic strategies employed for the construction of thiopyran-fused heterocycles. In particular, this article discusses synthetic methods for the fusion of thiopyran with heterocycles such as indole, quinoline, pyrimidine, pyridine, thiophene, chromene, oxazole, pyrazole, pyran and furan and covers the literature from 2013 to 2024. The most common precursors for thiopyrano[2,3-b]indoles, thiopyranoquinolines and thiopyranothiazoles are indoline-2-thione, 2-mercaptoquinoline-3-carbaldehyde and thiazolidinone, respectively, and various reactions involving these are described in detail here. Asymmetric syntheses of thiopyranoindoles achieved using chiral catalysts based on thiourea, proline and metal complexes are also included. The biological activity associated with some compounds is also discussed.
Collapse
Affiliation(s)
- Ani Deepthi
- Department of Chemistry, University of Kerala, Kariavattom, Trivandrum - 695581, Kerala, India.
| | | | - Devika Krishnan
- Department of Chemistry, University of Kerala, Kariavattom, Trivandrum - 695581, Kerala, India.
| |
Collapse
|
2
|
Chahat, Bhatia R, Kumar B. p53 as a potential target for treatment of cancer: A perspective on recent advancements in small molecules with structural insights and SAR studies. Eur J Med Chem 2023; 247:115020. [PMID: 36543034 DOI: 10.1016/j.ejmech.2022.115020] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2022] [Revised: 12/05/2022] [Accepted: 12/11/2022] [Indexed: 12/23/2022]
Abstract
Cancer represents one of the world's biggest hazardous diseases. p53 is the uttermost researched tumour suppressor protein. It is commonly considered the "guardian of the genome," performing a critical function in genetic stability maintenance through controlling the cell cycle, programmed cell death, DNA repair, aging, and angiogenesis. The abnormalities in p53 lead to genetic instability and plays a significant role in carcinogenesis. The role of p53 in tumour suppression is emphasized in addition by the observation that primary silencing with this protein occurred in more than 50% of cancers. MDM2, p53, and the p53-MDM2 connections are well-known targets for the prevention and treatment of cancer. Moreover, in tumors with wild-type p53, their efficacy is decreased due to MDM2 enlargement or by the gradual decrease of MDM2 blocker ARF. As a result, improving p53 activity in cancerous cells provides a promising anticancer strategy. Various techniques are now being investigated, and addressing the p53-MDM2 interaction had also evolved as a potentially feasible strategy for contending with tumors. Both p53 and MDM2, interact via an autoregulation response signal: p53 activity induces MDM2 transcription, which in response interacts with p53's N-terminal transactivation domain, inhibiting its transcriptional activity. This article provides information on the current scenario of anti-tumor activities, with a particular emphasis on structure-activity relationship characteristics (SAR) against the p53-MDM2 to treat cancer. The primary purpose of this review is to cover recent advancements in the creation and testing of anticancer drugs that target the p53-MDM2 structure. This review contains different heterocyclic moieties which show significant results toward cancer. A mechanistic route is shown here, demonstrating both normal and malignant conditions via several stressed factors. Several compounds entered clinical trials as p53-MDM2 inhibitors for the treatment of cancer.
Collapse
Affiliation(s)
- Chahat
- Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Ghal Kalan, Ferozpur G.T. Road MOGA, 142001, Punjab, India
| | - Rohit Bhatia
- Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Ghal Kalan, Ferozpur G.T. Road MOGA, 142001, Punjab, India
| | - Bhupinder Kumar
- Department of Pharmaceutical Sciences, HNB Garhwal University, Chauras Campus, Srinagar, Garhwal, Uttarakhand, 246174, India.
| |
Collapse
|
3
|
Benaglia M, Greco SJ, Westphal R, Venturini Filho E, Medici F. Stereoselective Domino Reactions in the Synthesis of Spiro Compounds. SYNTHESIS-STUTTGART 2022. [DOI: 10.1055/a-1771-0641] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
AbstractThis review summarizes the latest developments in asymmetric domino reactions, with the emphasis on the preparation of spiro compounds. Discussions on the stereoselectivity of the transformations, the reaction mechanisms, the rationalization of the stereochemical outcome, and the applications of domino reactions to the synthesis of biologically active molecules and natural products are included when appropriate.1 Introduction2 Asymmetric Domino Reactions2.1 Domino Reactions Initiated by Michael Reactions2.2 Domino Reactions Initiated by Mannich Reactions2.3 Domino Reactions Initiated by Knoevenagel Reactions2.4 Domino Reactions Initiated by Cycloaddition Reactions2.5 Domino Reactions Initiated by Metal Insertion2.6 Other Mechanisms3 Conclusion
Collapse
|
4
|
Han B, He XH, Liu YQ, He G, Peng C, Li JL. Asymmetric organocatalysis: an enabling technology for medicinal chemistry. Chem Soc Rev 2021; 50:1522-1586. [PMID: 33496291 DOI: 10.1039/d0cs00196a] [Citation(s) in RCA: 170] [Impact Index Per Article: 56.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The efficacy and synthetic versatility of asymmetric organocatalysis have contributed enormously to the field of organic synthesis since the early 2000s. As asymmetric organocatalytic methods mature, they have extended beyond the academia and undergone scale-up for the production of chiral drugs, natural products, and enantiomerically enriched bioactive molecules. This review provides a comprehensive overview of the applications of asymmetric organocatalysis in medicinal chemistry. A general picture of asymmetric organocatalytic strategies in medicinal chemistry is firstly presented, and the specific applications of these strategies in pharmaceutical synthesis are systematically described, with a focus on the preparation of antiviral, anticancer, neuroprotective, cardiovascular, antibacterial, and antiparasitic agents, as well as several miscellaneous bioactive agents. The review concludes with a discussion of the challenges, limitations and future prospects for organocatalytic asymmetric synthesis of medicinally valuable compounds.
Collapse
Affiliation(s)
- Bo Han
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
| | - Xiang-Hong He
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
| | - Yan-Qing Liu
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
| | - Gu He
- State Key Laboratory of Biotherapy and Cancer Centre, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Cheng Peng
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
| | - Jun-Long Li
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China. and Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University, Chengdu 610106, China.
| |
Collapse
|
5
|
Mu J, Xie X, Xiong S, Zhang Y, Wang Y, Zhao Q, Zhu H, Huang W, He G. Discovery of spirooxindole–ferrocene hybrids as novel MDM2 inhibitors. CHINESE CHEM LETT 2021. [DOI: 10.1016/j.cclet.2021.01.033] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
6
|
Wang X, Ni D, Liu Y, Lu S. Rational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions. Front Chem 2021; 9:682675. [PMID: 34017824 PMCID: PMC8128998 DOI: 10.3389/fchem.2021.682675] [Citation(s) in RCA: 53] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2021] [Accepted: 04/09/2021] [Indexed: 12/12/2022] Open
Abstract
Protein-protein interactions (PPIs) are well-established as a class of promising drug targets for their implications in a wide range of biological processes. However, drug development toward PPIs is inevitably hampered by their flat and wide interfaces, which generally lack suitable pockets for ligand binding, rendering most PPI systems "undruggable." Here, we summarized drug design strategies for developing peptide-based PPI inhibitors. Importantly, several quintessential examples toward well-established PPI targets such as Bcl-2 family members, p53-MDM2, as well as APC-Asef are presented to illustrate the detailed schemes for peptide-based PPI inhibitor development and optimizations. This review supplies a comprehensive overview of recent progresses in drug discovery targeting PPIs through peptides or peptidomimetics, and will shed light on future therapeutic agent development toward the historically "intractable" PPI systems.
Collapse
Affiliation(s)
- Xuefei Wang
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao-Tong University School of Medicine, Shanghai, China
| | - Duan Ni
- The Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia
| | - Yaqin Liu
- Medicinal Bioinformatics Center, Shanghai Jiao-Tong University School of Medicine, Shanghai, China
| | - Shaoyong Lu
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao-Tong University School of Medicine, Shanghai, China
- Medicinal Bioinformatics Center, Shanghai Jiao-Tong University School of Medicine, Shanghai, China
| |
Collapse
|
7
|
Xie X, Xiong SS, Li X, Huang H, Wu FB, Shen PF, Peng C, He G, Han B. Design and organocatalytic synthesis of spirooxindole–cyclopentene–isoxazole hybrids as novel MDM2–p53 inhibitors. Org Chem Front 2021. [DOI: 10.1039/d0qo01626h] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
An organocatalytic 1,6-cycloaddition with exclusive α-regioselectivity to synthesize designed spirooxindole–cyclopentene–isoxazole hybrids as novel MDM2–p53 inhibitors.
Collapse
Affiliation(s)
- Xin Xie
- College of Medical Technology and School of Pharmacy
- State Key Laboratory of Southwestern Chinese Medicine Resources
- Chengdu University of Traditional Chinese Medicine
- Chengdu 611137
- China
| | - Shan-Shan Xiong
- State Key Laboratory of Biotherapy and Department of Pharmacy
- West China Hospital
- Sichuan University
- Chengdu
- China
| | - Xiang Li
- College of Medical Technology and School of Pharmacy
- State Key Laboratory of Southwestern Chinese Medicine Resources
- Chengdu University of Traditional Chinese Medicine
- Chengdu 611137
- China
| | - He Huang
- College of Medical Technology and School of Pharmacy
- State Key Laboratory of Southwestern Chinese Medicine Resources
- Chengdu University of Traditional Chinese Medicine
- Chengdu 611137
- China
| | - Feng-Bo Wu
- College of Medical Technology and School of Pharmacy
- State Key Laboratory of Southwestern Chinese Medicine Resources
- Chengdu University of Traditional Chinese Medicine
- Chengdu 611137
- China
| | - Peng-Fei Shen
- State Key Laboratory of Biotherapy and Department of Pharmacy
- West China Hospital
- Sichuan University
- Chengdu
- China
| | - Cheng Peng
- College of Medical Technology and School of Pharmacy
- State Key Laboratory of Southwestern Chinese Medicine Resources
- Chengdu University of Traditional Chinese Medicine
- Chengdu 611137
- China
| | - Gu He
- State Key Laboratory of Biotherapy and Department of Pharmacy
- West China Hospital
- Sichuan University
- Chengdu
- China
| | - Bo Han
- College of Medical Technology and School of Pharmacy
- State Key Laboratory of Southwestern Chinese Medicine Resources
- Chengdu University of Traditional Chinese Medicine
- Chengdu 611137
- China
| |
Collapse
|
8
|
Patel KR, Patel HD. p53: An Attractive Therapeutic Target for Cancer. Curr Med Chem 2020; 27:3706-3734. [PMID: 31223076 DOI: 10.2174/1573406415666190621094704] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2018] [Revised: 02/28/2019] [Accepted: 04/16/2019] [Indexed: 02/08/2023]
Abstract
Cancer is a leading cause of death worldwide. It initiates when cell cycle regulatory genes lose their function either by environmental and/or by internal factors. Tumor suppressor protein p53, known as "Guardian of genome", plays a central role in maintaining genomic stability of the cell. Mutation of TP53 is documented in more than 50% of human cancers, usually by overexpression of negative regulator protein MDM2. Hence, reactivation of p53 by blocking the protein-protein interaction between the murine double minute 2 (MDM2) and the tumor suppressor protein p53 has become the most promising therapeutic strategy in oncology. Several classes of small molecules have been identified as potent, selective and efficient p53-MDM2 inhibitors. Herein, we review the druggability of p53-MDM2 inhibitors and their optimization approaches as well as clinical candidates categorized by scaffold type.
Collapse
Affiliation(s)
- Krupa R Patel
- Department of Chemistry, School of Sciences, Gujarat University, Ahmedabad 380009, Gujarat, India
| | - Hitesh D Patel
- Department of Chemistry, School of Sciences, Gujarat University, Ahmedabad 380009, Gujarat, India
| |
Collapse
|
9
|
Zhou LM, Qu RY, Yang GF. An overview of spirooxindole as a promising scaffold for novel drug discovery. Expert Opin Drug Discov 2020; 15:603-625. [PMID: 32106717 DOI: 10.1080/17460441.2020.1733526] [Citation(s) in RCA: 120] [Impact Index Per Article: 30.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Introduction: Spirooxindole, a unique and versatile scaffold, has been widely studied in some fields such as pharmaceutical chemistry and synthetic chemistry. Especially in the application of medicine, quite a few compounds featuring spirooxindole motif have displayed excellent and broad pharmacological activities. Many identified candidate molecules have been used in clinical trials, showing promising prospects.Areas covered: This article offers an overview of different applications and developments of spirooxindoles (including the related natural products and their derivatives) in the process of drug innovation, including such as in anticancer, antimicrobial, anti-inflammatory, analgesic, antioxidant, antimalarial, and antiviral activities. Furthermore, the crucial structure-activity relationships, molecular mechanisms, pharmacokinetic properties, and main synthetic methods of spirooxindoles-based derivatives are also reviewed.Expert opinion: Recent progress in the biological activity profiles of spirooxindole derivatives have demonstrated their significant position in present-day drug discovery. Furthermore, we believe that the multidirectional development of novel drugs containing this core scaffold will continue to be the research hotspot in medicinal chemistry in the future.
Collapse
Affiliation(s)
- Li-Ming Zhou
- Key Laboratory of Pesticide & Chemical Biology of Ministry of Education, International Joint Research Center for Intelligent Biosensor Technology and Health, College of Chemistry, Central China Normal University, Wuhan, P. R. China
| | - Ren-Yu Qu
- Key Laboratory of Pesticide & Chemical Biology of Ministry of Education, International Joint Research Center for Intelligent Biosensor Technology and Health, College of Chemistry, Central China Normal University, Wuhan, P. R. China
| | - Guang-Fu Yang
- Key Laboratory of Pesticide & Chemical Biology of Ministry of Education, International Joint Research Center for Intelligent Biosensor Technology and Health, College of Chemistry, Central China Normal University, Wuhan, P. R. China
| |
Collapse
|
10
|
Pathania S, Narang RK, Rawal RK. Role of sulphur-heterocycles in medicinal chemistry: An update. Eur J Med Chem 2019; 180:486-508. [PMID: 31330449 DOI: 10.1016/j.ejmech.2019.07.043] [Citation(s) in RCA: 171] [Impact Index Per Article: 34.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2019] [Revised: 07/10/2019] [Accepted: 07/12/2019] [Indexed: 12/13/2022]
Abstract
From many decades, S-heterocycles have maintained their status as an important part and core of FDA approved drugs and medicinally active compounds. With exhaustive exploration of nitrogen heterocycles in medicinal chemistry, researchers have shifted their interest towards other heterocycles, especially, S-heterocycles. Thus several attempts have been made to synthesize a variety of new sulphur containing compounds with high medicinal value and low toxicity profile, in comparison to previous N-heterocycles. Till today, S-heterocycle containing compounds have been largely reported as anticancer, antidiabetic, antimicrobial, antihypertension, antivral, antinflammatory etc. In this review, the authors have tried to provide a critical analysis of synthesis and medicinal attributes of sulphur containing heterocycles such as thiirane, thiophene, thiazole, thiopyran, thiazolidine etc reported within last five years to emphasize the significance and usefulness of these S-heterocycles in the drug discovery process.
Collapse
Affiliation(s)
- Shelly Pathania
- Department of Pharmaceutical Chemistry, Indo-Soviet Friendship College of Pharmacy (ISFCP), Moga, 142001, Punjab, India; Research Scholar, Maharaja Ranjit Singh Punjab Technical University, Bathinda, Punjab, 151001, India
| | - Raj Kumar Narang
- Department of Pharmaceutical Chemistry, Indo-Soviet Friendship College of Pharmacy (ISFCP), Moga, 142001, Punjab, India
| | - Ravindra K Rawal
- Department of Chemistry, Maharishi Markandeshwar (Deemed to Be University), Mullana, 133207, Haryana, India.
| |
Collapse
|
11
|
Liu W, Chen S, Zhang F, He S, Wang S, Sheng C. Design, synthesis and biological evaluation of novel antitumor spirodihydrothiopyran-oxindole derivatives. Bioorg Med Chem Lett 2019; 29:1636-1642. [DOI: 10.1016/j.bmcl.2019.04.037] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2019] [Revised: 04/16/2019] [Accepted: 04/25/2019] [Indexed: 12/17/2022]
|
12
|
Gollner A, Weinstabl H, Fuchs JE, Rudolph D, Garavel G, Hofbauer KS, Karolyi‐Oezguer J, Gmaschitz G, Hela W, Kerres N, Grondal E, Werni P, Ramharter J, Broeker J, McConnell DB. Targeted Synthesis of Complex Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-ones by Intramolecular Cyclization of Azomethine Ylides: Highly Potent MDM2-p53 Inhibitors. ChemMedChem 2019; 14:88-93. [PMID: 30458062 PMCID: PMC6590160 DOI: 10.1002/cmdc.201800617] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2018] [Revised: 11/08/2018] [Indexed: 12/26/2022]
Abstract
Mouse double minute 2 (MDM2) is a main and direct inhibitor of the crucial tumor suppressor p53. Reports from initial clinical trials showed that blocking this interaction with a small-molecule inhibitor can have great value in the treatment of cancer for patients with p53 wild-type tumors; however, it also revealed dose-limiting hematological toxicities and drug-induced resistance as main issues. To overcome the former, an inhibitor with superior potency and pharmacokinetic properties to ultimately achieve full efficacy with less-frequent dosing schedules is required. Toward this aim, we optimized our recently reported spiro-oxindole inhibitors by focusing on the crucial interaction with the amino acid side chain of His96MDM2 . The designed molecules required the targeted synthesis of structurally complex spiro[indole-3,2'-pyrrolo[2,3-c]pyrrole]-2,4'-diones for which we developed an unprecedented intramolecular azomethine ylide cycloaddition and investigated the results by computational methods. One of the new compounds showed superior cellular potency over previously reported BI-0252. This finding is a significant step toward an inhibitor suitable to potentially mitigate hematological on-target adverse effects.
Collapse
Affiliation(s)
- Andreas Gollner
- Boehringer Ingelheim RCV GmbH & Co. KGDr. Boehringer-Gasse 5-11A1121ViennaAustria
| | - Harald Weinstabl
- Boehringer Ingelheim RCV GmbH & Co. KGDr. Boehringer-Gasse 5-11A1121ViennaAustria
| | - Julian E. Fuchs
- Boehringer Ingelheim RCV GmbH & Co. KGDr. Boehringer-Gasse 5-11A1121ViennaAustria
| | - Dorothea Rudolph
- Boehringer Ingelheim RCV GmbH & Co. KGDr. Boehringer-Gasse 5-11A1121ViennaAustria
| | - Geraldine Garavel
- Boehringer Ingelheim RCV GmbH & Co. KGDr. Boehringer-Gasse 5-11A1121ViennaAustria
| | - Karin S. Hofbauer
- Boehringer Ingelheim RCV GmbH & Co. KGDr. Boehringer-Gasse 5-11A1121ViennaAustria
| | - Jale Karolyi‐Oezguer
- Boehringer Ingelheim RCV GmbH & Co. KGDr. Boehringer-Gasse 5-11A1121ViennaAustria
| | - Gerhard Gmaschitz
- Boehringer Ingelheim RCV GmbH & Co. KGDr. Boehringer-Gasse 5-11A1121ViennaAustria
| | - Wolfgang Hela
- Boehringer Ingelheim RCV GmbH & Co. KGDr. Boehringer-Gasse 5-11A1121ViennaAustria
| | - Nina Kerres
- Boehringer Ingelheim RCV GmbH & Co. KGDr. Boehringer-Gasse 5-11A1121ViennaAustria
| | - Elisabeth Grondal
- Boehringer Ingelheim RCV GmbH & Co. KGDr. Boehringer-Gasse 5-11A1121ViennaAustria
| | - Patrick Werni
- Boehringer Ingelheim RCV GmbH & Co. KGDr. Boehringer-Gasse 5-11A1121ViennaAustria
| | - Juergen Ramharter
- Boehringer Ingelheim RCV GmbH & Co. KGDr. Boehringer-Gasse 5-11A1121ViennaAustria
| | - Joachim Broeker
- Boehringer Ingelheim RCV GmbH & Co. KGDr. Boehringer-Gasse 5-11A1121ViennaAustria
| | - Darryl B. McConnell
- Boehringer Ingelheim RCV GmbH & Co. KGDr. Boehringer-Gasse 5-11A1121ViennaAustria
| |
Collapse
|
13
|
Xiao G, Chen T, Ma C, Xing D, Hu W. Rh(II)/Chiral Phosphoric Acid-Cocatalyzed Enantioselective Synthesis of Spirooxindole-Fused Thiaindans. Org Lett 2018; 20:4531-4535. [PMID: 30044637 DOI: 10.1021/acs.orglett.8b01833] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
An asymmetric strategy for the construction of chiral sulfur-containing spirooxindole-fused heterocycles was achieved via a rhodium(II)/chiral phosphoric acid-cocatalyzed reaction between 2-mercaptophenyl ketones and 3-diazooxindoles. With this method, a series of spirooxindole-thiaindan derivatives bearing two contiguous quaternary carbon stereogenic centers were obtained in high yields with high diastereoselectivities and high-to-excellent enantioselectivities.
Collapse
Affiliation(s)
- Guolan Xiao
- Shanghai Engineering Research Centre of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering , East China Normal University , 3663 North Zhongshan Road , Shanghai 200062 , China
| | - Tiantian Chen
- Shanghai Engineering Research Centre of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering , East China Normal University , 3663 North Zhongshan Road , Shanghai 200062 , China
| | - Chaoqun Ma
- Shanghai Engineering Research Centre of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering , East China Normal University , 3663 North Zhongshan Road , Shanghai 200062 , China
| | - Dong Xing
- Shanghai Engineering Research Centre of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering , East China Normal University , 3663 North Zhongshan Road , Shanghai 200062 , China
| | - Wenhao Hu
- Shanghai Engineering Research Centre of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering , East China Normal University , 3663 North Zhongshan Road , Shanghai 200062 , China.,School of Pharmaceutical Sciences , Sun Yat-sen University , Guangzhou 510006 , China
| |
Collapse
|
14
|
Zhou Y, Ju Y, Yang Y, Sang Z, Wang Z, He G, Yang T, Luo Y. Discovery of hybrids of indolin-2-one and nitroimidazole as potent inhibitors against drug-resistant bacteria. J Antibiot (Tokyo) 2018; 71:887-897. [DOI: 10.1038/s41429-018-0076-5] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2018] [Revised: 05/20/2018] [Accepted: 06/04/2018] [Indexed: 12/15/2022]
|
15
|
Davison EK, Hume PA, Sperry J. Total Synthesis of an Isatis indigotica-Derived Alkaloid Using a Biomimetic Thio-Diels–Alder Reaction. Org Lett 2018; 20:3545-3548. [DOI: 10.1021/acs.orglett.8b01321] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- Emma K. Davison
- School of Chemical Sciences, University of Auckland, 23 Symonds Street, Auckland, New Zealand
| | - Paul A. Hume
- School of Chemical Sciences, University of Auckland, 23 Symonds Street, Auckland, New Zealand
| | - Jonathan Sperry
- School of Chemical Sciences, University of Auckland, 23 Symonds Street, Auckland, New Zealand
| |
Collapse
|
16
|
Sengoku T, Hayashi D, Takahashi M, Yoda H. Electrophilic Amide Allylation of 3-Heterosubstituted Oxindoles: A Route to Spirocyclic 2-Oxindoles Containing the α-Methylene-γ-butyrolactam Structure. European J Org Chem 2018. [DOI: 10.1002/ejoc.201800084] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- Tetsuya Sengoku
- Department of Applied Chemistry; Faculty of Engineering; Shizuoka University; 3-5-1 Johoku, Naka-ku 432-8561 Hamamatsu Japan
| | - Daichi Hayashi
- Department of Applied Chemistry; Faculty of Engineering; Shizuoka University; 3-5-1 Johoku, Naka-ku 432-8561 Hamamatsu Japan
| | - Masaki Takahashi
- Department of Applied Chemistry; Faculty of Engineering; Shizuoka University; 3-5-1 Johoku, Naka-ku 432-8561 Hamamatsu Japan
| | - Hidemi Yoda
- Department of Applied Chemistry; Faculty of Engineering; Shizuoka University; 3-5-1 Johoku, Naka-ku 432-8561 Hamamatsu Japan
| |
Collapse
|
17
|
Wang S, Chen S, Guo Z, He S, Zhang F, Liu X, Chen W, Zhang S, Sheng C. Synthesis of spiro-tetrahydrothiopyran-oxindoles by Michael–aldol cascade reactions: discovery of potential P53-MDM2 inhibitors with good antitumor activity. Org Biomol Chem 2018; 16:625-634. [DOI: 10.1039/c7ob02726e] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Novel one-pot Michael–aldol cascade reactions were used to efficiently construct spiro-tetrahydrothiopyran-oxindoles with good in vitro antitumor activity.
Collapse
Affiliation(s)
- Shengzheng Wang
- Department of Medicinal Chemistry
- School of Pharmacy
- Fourth Military Medical University
- Xi'an 710032
- P.R. China
| | - Shuqiang Chen
- Department of Medicinal Chemistry
- School of Pharmacy
- Second Military Medical University
- Shanghai 200433
- People's Republic of China
| | - Zhongjie Guo
- Department of Medicinal Chemistry
- School of Pharmacy
- Fourth Military Medical University
- Xi'an 710032
- P.R. China
| | - Shipeng He
- Department of Medicinal Chemistry
- School of Pharmacy
- Second Military Medical University
- Shanghai 200433
- People's Republic of China
| | - Fan Zhang
- Department of Medicinal Chemistry
- School of Pharmacy
- Fourth Military Medical University
- Xi'an 710032
- P.R. China
| | - Xueying Liu
- Department of Medicinal Chemistry
- School of Pharmacy
- Fourth Military Medical University
- Xi'an 710032
- P.R. China
| | - Weiping Chen
- Department of Medicinal Chemistry
- School of Pharmacy
- Fourth Military Medical University
- Xi'an 710032
- P.R. China
| | - Shengyong Zhang
- Department of Medicinal Chemistry
- School of Pharmacy
- Fourth Military Medical University
- Xi'an 710032
- P.R. China
| | - Chunquan Sheng
- Department of Medicinal Chemistry
- School of Pharmacy
- Second Military Medical University
- Shanghai 200433
- People's Republic of China
| |
Collapse
|